Agriculture · Founded 2002 · www.osawalseeds.com · NSE · ISIN INE00IK01029
No Notes Added Yet
Business
Shree Oswal Seeds and Chemicals Ltd. (OSWALSEEDS) is an Indian agriculture company primarily engaged in two core areas: seeds and agricultural chemicals. The company likely develops, produces, processes, and markets a range of seeds, including hybrid seeds, for various crops suitable for the Indian subcontinent. Additionally, it manufactures and distributes agrochemicals such as pesticides, insecticides, fungicides, herbicides, and plant growth regulators. Its core business model involves selling these products directly to farmers, through a network of distributors and retailers, to enhance agricultural productivity and protect crops. Revenue is generated from the sales of these seed and chemical products.
Revenue Mix
Based on the company name, the two major business segments are:
Seeds: This segment would include the development, production, processing, and sale of various crop seeds (e.g., cereals, pulses, oilseeds, cotton, vegetables).
Chemicals: This segment encompasses the manufacturing and distribution of agrochemicals such as crop protection products (pesticides, insecticides, fungicides, herbicides) and nutrient management solutions.
Specific revenue contributions from each segment are not publicly available in this overview.
Industry
The company operates within the Indian agriculture sector, which is a foundational part of the economy but highly dependent on monsoon patterns, government policies, and global commodity prices. The seeds industry in India is characterized by the presence of large multinational corporations (MNCs) with strong R&D capabilities, national players with established regional networks, and numerous smaller local companies. The agrochemical industry is also competitive, with both domestic and international players offering a wide range of products. Shree Oswal Seeds and Chemicals Ltd. likely positions itself as a regional or national player, focusing on specific crop varieties or chemical formulations relevant to Indian farming practices, competing on product efficacy, price, and distribution reach.
MOAT
Brand Reputation & Farmer Trust: A long-standing presence and consistent product performance can build significant trust among farmers, which is crucial in the agriculture sector.
Distribution Network: An extensive and efficient network of dealers and distributors, especially in rural areas, can be a strong moat, enabling widespread product reach.
Germplasm Bank & R&D (Moderate): While not at the scale of global giants, a proprietary germplasm bank and focused R&D on specific hybrid seeds suited for Indian conditions can offer a competitive edge.
Regulatory Approvals: Obtaining necessary approvals for new seed varieties and chemical formulations can be a time-consuming and complex process, providing a barrier to entry for new competitors.
Growth Drivers
Increasing Food Demand: India's growing population drives sustained demand for food grains, requiring higher agricultural productivity and quality seeds.
Hybrid Seed Adoption: Continued shift towards high-yielding hybrid and improved seeds to boost farm output and farmer income.
Crop Protection Needs: Growing awareness and necessity for effective crop protection against pests and diseases, leading to increased demand for agrochemicals.
Government Support: Initiatives and policies by the Indian government to support agriculture, such as irrigation schemes, minimum support prices, and subsidies, can indirectly boost demand for agri-inputs.
New Product Launches: Introduction of new, more efficient, and climate-resilient seed varieties and advanced agrochemical formulations.
Risks
Monsoon Dependence: Indian agriculture is heavily reliant on monsoons; irregular or deficient rainfall can severely impact demand for seeds and chemicals, leading to revenue volatility.
Pest Outbreaks & Crop Diseases: Unpredictable outbreaks can necessitate emergency demand for specific chemicals but also lead to crop losses, impacting farmer purchasing power.
Regulatory & Policy Changes: Changes in government policies regarding subsidies, seed pricing, import/export duties, or environmental regulations for chemicals can impact profitability.
Raw Material Price Volatility: Fluctuations in the prices of key raw materials used in chemical manufacturing or seed production can affect margins.
Intense Competition: The presence of numerous domestic and international players in both seeds and chemicals leads to pricing pressure and market share battles.
Intellectual Property Rights (IPR) Issues: Protection of proprietary seed varieties from unauthorized duplication or sale can be a challenge.
Management & Ownership
Shree Oswal Seeds and Chemicals Ltd. is typically a promoter-driven company, common in India, where the founding family or individuals hold significant ownership and play a key role in strategic decision-making and day-to-day operations. The quality of management is often reflected in their experience within the agricultural sector, their vision for product innovation, market expansion, and ability to navigate the complex regulatory and environmental landscape of Indian farming. Their long-term commitment to the business, as evidenced by promoter shareholding, is usually a key factor for investors.
Outlook
Shree Oswal Seeds and Chemicals Ltd. operates in a fundamental sector with long-term growth potential driven by India's food security needs and the continuous drive for agricultural modernization. The company's focus on both seeds and chemicals provides diversification within the agri-input segment. The bullish case rests on its ability to develop and market successful new hybrid seeds and effective chemical solutions, expand its distribution network, and capitalize on government support for agriculture. However, the company faces inherent risks associated with the cyclical nature of agriculture, including monsoon variability, pest outbreaks, and commodity price fluctuations. Intense competition, regulatory changes, and the ability to consistently innovate and maintain product efficacy are crucial for sustained success. Therefore, the outlook is cautiously optimistic, dependent on effective risk management, continuous R&D, and strong market execution in a dynamic agricultural landscape.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 43 | 77 | 68 | 75 | 26 | 98 | 39 | 55 | 56 | 117 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 44 | 77 | 68 | 75 | 26 | 98 | 39 | 55 | 56 | 117 |
| Total Expenditure | 48 | 79 | 66 | 67 | 24 | 87 | 43 | 52 | 52 | 99 |
| Operating Profit | -5 | -2 | 2 | 8 | 2 | 11 | -4 | 3 | 4 | 18 |
| Interest | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -6 | -4 | 0 | 7 | 1 | 10 | -5 | 1 | 3 | 17 |
| Provision for Tax | -3 | -1 | 0 | 2 | 0 | 3 | -1 | 0 | 1 | 5 |
| Profit After Tax | -4 | -3 | 0 | 5 | 1 | 7 | -3 | 1 | 2 | 12 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -4 | -3 | 0 | 5 | 1 | 7 | -3 | 1 | 2 | 12 |
| Adjusted Earnings Per Share | -0.4 | -0.3 | 0 | 0.6 | 0.1 | 0.8 | -0.4 | 0.1 | 0.2 | 1.3 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 18 | 126 | 117 | 161 | 241 | 272 | 269 | 246 | 267 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 18 | 127 | 117 | 161 | 241 | 272 | 269 | 246 | 267 |
| Total Expenditure | 16 | 120 | 110 | 154 | 230 | 260 | 268 | 236 | 246 |
| Operating Profit | 2 | 7 | 7 | 8 | 11 | 12 | 1 | 10 | 21 |
| Interest | 1 | 2 | 2 | 2 | 3 | 4 | 6 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Exceptional Income / Expenses | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 4 | 4 | 5 | 8 | 8 | -5 | 5 | 16 |
| Provision for Tax | 0 | 1 | 1 | 1 | 2 | 2 | -1 | 2 | 5 |
| Profit After Tax | 1 | 3 | 3 | 4 | 5 | 6 | -4 | 4 | 12 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 3 | 3 | 4 | 5 | 6 | -4 | 4 | 12 |
| Adjusted Earnings Per Share | 0.2 | 0.3 | 0.3 | 0.4 | 0.6 | 0.6 | -0.5 | 0.4 | 1.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -9% | 1% | 16% | 0% |
| Operating Profit CAGR | 900% | -3% | 7% | 0% |
| PAT CAGR | 0% | -7% | 6% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -17% | -40% | 12% | NA% |
| ROE Average | 8% | 4% | 8% | 9% |
| ROCE Average | 10% | 8% | 10% | 10% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 12 | 27 | 30 | 33 | 39 | 44 | 40 | 44 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 2 | 0 | 0 | 6 | 4 | 2 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 |
| Total Current Liabilities | 38 | 34 | 36 | 54 | 77 | 84 | 84 | 60 |
| Total Liabilities | 52 | 61 | 66 | 93 | 120 | 130 | 123 | 104 |
| Fixed Assets | 2 | 2 | 4 | 4 | 4 | 4 | 7 | 6 |
| Other Non-Current Assets | 1 | 0 | 1 | 1 | 0 | 2 | 3 | 4 |
| Total Current Assets | 49 | 59 | 61 | 88 | 115 | 124 | 113 | 94 |
| Total Assets | 52 | 61 | 66 | 93 | 120 | 130 | 123 | 104 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 4 | 2 | 1 | 2 | 5 | 3 |
| Cash Flow from Operating Activities | -10 | -10 | -4 | -11 | 5 | 10 | -15 | 24 |
| Cash Flow from Investing Activities | -0 | 1 | -3 | -0 | -1 | -2 | -3 | -1 |
| Cash Flow from Financing Activities | 10 | 13 | 4 | 10 | -4 | -4 | 17 | -26 |
| Net Cash Inflow / Outflow | 0 | 3 | -3 | -1 | 1 | 3 | -2 | -3 |
| Closing Cash & Cash Equivalent | 1 | 4 | 2 | 1 | 2 | 5 | 3 | 0 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.17 | 0.31 | 0.33 | 0.4 | 0.59 | 0.62 | -0.45 | 0.39 |
| CEPS(Rs) | 0.19 | 0.35 | 0.37 | 0.43 | 0.64 | 0.67 | -0.4 | 0.44 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 1.86 | 2.9 | 3.24 | 3.64 | 4.23 | 4.85 | 4.4 | 4.78 |
| Core EBITDA Margin(%) | 9.81 | 4.94 | 5.97 | 4.76 | 4.36 | 4.37 | 0.37 | 3.89 |
| EBIT Margin(%) | 11.15 | 4.91 | 5.72 | 4.65 | 4.24 | 4.26 | 0.22 | 3.81 |
| Pre Tax Margin(%) | 7.82 | 3 | 3.63 | 3.14 | 3.15 | 2.9 | -2 | 2.08 |
| PAT Margin (%) | 6.24 | 2.23 | 2.61 | 2.26 | 2.26 | 2.1 | -1.55 | 1.44 |
| Cash Profit Margin (%) | 6.76 | 2.5 | 2.87 | 2.45 | 2.42 | 2.25 | -1.35 | 1.64 |
| ROA(%) | 2.15 | 4.99 | 4.78 | 4.59 | 5.12 | 4.56 | -3.29 | 3.11 |
| ROE(%) | 9.38 | 14.66 | 10.85 | 11.62 | 15.12 | 13.75 | -9.84 | 8.41 |
| ROCE(%) | 5.44 | 14.19 | 12.1 | 11.01 | 13.02 | 14.01 | 0.63 | 9.88 |
| Receivable days | 226.2 | 31.78 | 36.28 | 20.96 | 19.28 | 18.47 | 17.5 | 22.27 |
| Inventory Days | 670.23 | 107.51 | 129.29 | 131.23 | 124.26 | 128.52 | 125.98 | 109.99 |
| Payable days | 334.05 | 36.65 | 17.27 | 3.04 | 3.88 | 4.34 | 3.98 | 5.72 |
| PER(x) | 0 | 15.15 | 11.51 | 12.88 | 15.99 | 86.75 | 0 | 30.17 |
| Price/Book(x) | 0 | 1.61 | 1.18 | 1.41 | 2.25 | 11.16 | 6.62 | 2.43 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.93 | 0.49 | 0.55 | 0.55 | 0.53 | 1.95 | 1.22 | 0.6 |
| EV/Core EBITDA(x) | 16.54 | 9.44 | 8.98 | 11.46 | 11.99 | 44.13 | 293.97 | 15.01 |
| Net Sales Growth(%) | 0 | 605.79 | -7.41 | 38.02 | 49.19 | 13.23 | -1.21 | -8.59 |
| EBIT Growth(%) | 0 | 210.47 | 7.92 | 12.23 | 35.97 | 13.84 | -94.89 | 1481.73 |
| PAT Growth(%) | 0 | 152.55 | 8.09 | 19.85 | 48.89 | 4.98 | -172.92 | 184.81 |
| EPS Growth(%) | 0 | 76.82 | 8.09 | 19.85 | 48.89 | 4.99 | -172.91 | 184.81 |
| Debt/Equity(x) | 2.08 | 0.9 | 1.02 | 1.3 | 1.08 | 0.92 | 1.59 | 0.96 |
| Current Ratio(x) | 1.3 | 1.73 | 1.69 | 1.63 | 1.51 | 1.48 | 1.35 | 1.55 |
| Quick Ratio(x) | 0.43 | 0.51 | 0.56 | 0.24 | 0.34 | 0.25 | 0.36 | 0.47 |
| Interest Cover(x) | 3.34 | 2.57 | 2.74 | 3.08 | 3.89 | 3.13 | 0.1 | 2.19 |
| Total Debt/Mcap(x) | 0 | 0.56 | 0.86 | 0.92 | 0.48 | 0.08 | 0.24 | 0.39 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.66 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 |
| FII | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 30.34 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.37 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 2.78 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -9% | +1% | +16% | — |
| Operating Profit CAGR | +900% | -3% | +7% | — |
| PAT CAGR | — | -7% | +6% | — |
| Share Price CAGR | -17% | -40% | +12% | — |
| ROE Average | +8% | +4% | +8% | +9% |
| ROCE Average | +10% | +8% | +10% | +10% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.66 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 | 66.63 |
| FII | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 30.34 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 | 33.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.37 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 2.78 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 | 9.15 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.